Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant TP chemotherapy after radiotherapy or chemoradiation in cervical cancer with residual HPV DNA
ChiCTR-IIR-17012655Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Fujian Medical University
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by Second Affiliated Hospital of Fujian Medical University. Primary endpoint: Relapse-free survival. Started Mar 2018; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-IIR-17012655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012655.